
Global pharmaceutical powerhouse Lupin Limited today announced a monumental achievement in its commitment to sustainable growth, securing an S&P Global ESG Score of 91 for the year 2025. This exceptional rating places Lupin among an exclusive group of companies globally to exceed the coveted 90-point mark, setting a new, stringent standard for Environmental, Social, and Governance (ESG) performance in the pharmaceutical industry.
Lupin’s score of 91 is significantly higher than the pharmaceutical industry average of 28, underscoring its market leadership not just in therapeutics but also in responsible business practices.
Phenomenal Trajectory of Improvement
The achievement is a culmination of focused, strategic efforts over the last few years, reflecting one of the fastest rates of improvement among global pharmaceutical firms:
The company’s score has soared from a mere 17 in 2021 to an impressive 91 in 2025. This includes a robust 15-point increase from its score of 76 in the previous year, demonstrating accelerated commitment and execution.
Executive Commentary on the Distinction
Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, emphasized the rarity and significance of the rating. “Achieving a score above 90 in the S&P Global ESG ratings is a rare global distinction, highlighting our unwavering commitment to sustainability,” said Swaminathan.
“With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today but redefines and sets new standards for responsible growth. Our purpose-led strategy ensures that we provide healthcare solutions that generate lasting value for patients, communities, and stakeholders worldwide.”
Deep Dive into the ESG Progress
Lupin reported substantial progress across all three critical pillars that form the basis of the S&P Global Corporate Sustainability Assessment (CSA):
| ESG Pillar | Key Achievements and Focus Areas |
| Environmental Stewardship | Intensified efforts across climate action and resource management, including increased use of renewable energy, successful reduction of carbon emissions (Scope 1 & 2), and the critical achievement of water-positive operations for the fourth consecutive year. |
| Social Responsibility | Prioritizing its most important asset—its people—by focusing on employee well-being and promoting diversity and inclusion. This is complemented by strong external contributions through the launch of community health programs and significant support for societal healthcare access. |
| Corporate Governance | Strengthening the company’s foundation with enhanced transparency, upholding rigorous ethical business practices, fortifying overall corporate governance, and instituting effective board-level oversight to proactively manage ESG-related risks and seize opportunities. |
This record-breaking ESG score validates Lupin’s vision to embed sustainability at the core of its business strategy, confirming its standing as a truly purpose-led organization committed to a sustainable and equitable future.
